An Analysis of Bevacizumab or Cetuximab for CRC

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in patients with squamous non–small cell lung cancer.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old patient with lung-metastatic renal cell carcinoma.

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with transplant-eligible multiple myeloma and the data behind their decisions.